The U.S. Supreme Court on Monday declined to hear a lawsuit by CareDx over organ-rejection tests made by Natera and Eurofins Viracor, turning down another request to revisit the contentious issue of patent eligibility.
Tag Archive for: patent dispute
Pfizer and German partner BioNTech on Monday asked the U.S. Patent and Trademark Office to reconsider, and ultimately invalidate, Moderna’s patents over core technologies of the COVID-19 vaccine, Reuters reported.
Alkermes plc has entered into a settlement agreement with Teva Pharmaceuticals USA, Inc. to resolve the ongoing patent litigation between the parties in the U.S. District Court for the District of New Jersey related to VIVITROL® (naltrexone for extended-release injectable suspension).
Yesterday’s patent settlement comes as the biopharma industry is faced with one of its steepest patent cliffs. By 2030, nearly 200 medicines will go off-patent, of which 69 are blockbuster drugs.
Amgen Inc. convinced a U.S. appeals court on Wednesday to uphold patents that bar generic versions of its blockbuster psoriasis drug Otezla proposed by Zydus Pharmaceuticals and Novartis AG’s Sandoz Inc until 2028.
Gene-sequencing giant Illumina Inc. has settled a patent lawsuit brought by Maryland biotech company Ravgen Inc., which accused Illumina’s genetic tests of infringing its patents.
The U.S. Supreme Court is set to hear a bid by Amgen to revive patents on its cholesterol-lowering drug Repatha in a legal effort that rival Sanofi SA called a “blatant attempt” to squeeze competitors out of the market.
Moderna first sued Pfizer in August, accusing the company of violating its rights in three patents related to innovations that Cambridge, Massachusetts-based Moderna said it pioneered before the COVID-19 pandemic.
Eli Lilly & Co. must pay Teva Pharmaceuticals International GmbH $176.5 million after a trial to determine whether its migraine drug Emgality infringed three Teva patents, a Boston federal court jury decided on Wednesday.
As the biotech world awaits the announcement of Merck’s anticipated buyout of Seagen, an arbitrator came down on the side of Daiichi Sankyo in a patent battle against the Seattle-based biotech.
